Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in early breast cancer
NCT03691311Phase 1Unknown
- Sponsor
- Institut Català d'Oncologia
- Start
- Jul 2018
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of denosumab in breast cancer (2 arms), sponsored by Institut Català d'Oncologia. Primary endpoint: Antiproliferative and/or pro-apoptotic activity of denosumab at 4 weeks. Status: unknown.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03691311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691311.